Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.

The value of the 'classical' binary approaches to define genotypic sensitivity and phenotypic sensitivity scores for optimization of background HIV therapy in patients with extensive HIV drug ...